AdultPediatricDosage Forms & Strengths injection 50 units/mL (Vaqta adult dose) 1440 ELISA units/mL (Havrix adult dose) Hepatitis A Immunization Indicated as active immunization for any person seeking protection and for persons at risk for HAV infection At risk populations Chronic liver disease (eg, hepatitis B infection, hepatitis C infection, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, ALT or AST >2x ULN) HIV infection Men who have sex with men Injection or noninjection drug use Persons who are homeless Work with hepatitis A virus (eg, research laboratory, work with nonhuman primates with HAV infection) Travel in countries with high or intermediate endemic HAV infection Close, personal contact with international adoptee (eg, household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic HAV infection (administer dose 1 as soon as adoption planned, at least 2 weeks before adoptee’s arrival) Pregnancy if at risk for infection or severe outcome from infection during pregnancy Setting for exposure, including healthcare settings targeting services to injection or noninjection drugs users or group homes; nonresidential day care facilities for developmentally disabled persons 2-dose vaccination series ≥19 years: 1 mL IM (primary dose) Administer primary dose at least 2 weeks before expected exposure to HAV Havrix: Administer booster dose 6-12 mo after primary dose Vaqta, ACIP guidelines: Administer booster dose 6-18 mo after primary dose Preexposure protection against HAV for travelers (ACIP guidelines) 1 mL IM given at least 2 weeks before expected exposure to HAV For persons not previously vaccinated with hepatitis A vaccine, administer dose as soon as travel is considered, and complete 2-dose series according to routine schedule Also consider giving immune globulin for patients who are immunocompromised or have chronic liver disease, or those 40 yr or older who are otherwise healthy Postexposure prophylaxis (PEP) for HAV 1 mL IM A second dose is not required for PEP; however, for long-term immunity, ACIP recommends completing the 2-dose series Age ≥40 years: Consider the need to also give immunoglobulin Immunocompromised or chronic liver disease: Vaccine and immune globulin should be administered simultaneously at different anatomic sites Additional Information Up-to-date vaccination schedules available at http://www.cdc.gov/vaccines/default.htmDosage Forms & Strengths injection 25 units/0.5 mL (Vaqta pediatric dose) 720 ELISA units/0.5mL (Havrix pediatric dose) Hepatitis A Immunization Indicated as routine vaccination for children at least 12 months of age (ACIP guidelines) <12 months: Not indicated; if administered, not counted toward the routine 2-dose series ≥12 months through 18 years (2-dose series) Primary dose: 0.5 mL IM Havrix: Administer booster dose 6-12 mo after primary dose Vaqta, ACIP guidelines: Administer booster dose 6-18 mo after primary dose Children who have received 1 dose before age 24 months, should receive a second dose 6-18 months after the first dose Catch up schedule For any person ≥2 yr who has not already received hepatitis A vaccine series, give 2 doses separated by 6-18 months if immunity against hepatitis A virus infection is desired Minimum interval between the 2-dose series is 6 months Preexposure protection against HAV for travelers (ACIP guidelines) <6 months: Do not administer hepatitis A vaccine, but do administer immune globulin 6-11 months: 0.5 mL IM; this dose does not count toward routine 2-dose vaccination series 12 months through 18 years: 0.5 mL IM; if not previously vaccinated with hepatitis A vaccine, complete 2-dose series according to routine schedule Immunocompromised or chronic liver disease: 0.5 mL IM; also consider giving immune globulin Postexposure prophylaxis (PEP) for HAV 12 months through 18 years: 0.5 mL IM; if not previously vaccinated with hepatitis A vaccine, complete 2-dose series according to routine schedule Immunocompromised or chronic liver disease: Vaccine and immune globulin should be administered simultaneously at different anatomic sites International travel Persons traveling to or working in countries with high or intermediate endemic hepatitis A Infants age 6-11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between 12 and 23 months of age Unvaccinated >12 months: Administer dose 1 as soon as travel is considered; give dose 2 after 6 months Interaction CheckerEnter a drug name and hepatitis A vaccine inactivatedNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)belimumabbelimumab decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.Serious - Use Alternative (38)adalimumabadalimumab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.alefaceptalefacept decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.anakinraanakinra decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.antithymocyte globulin equineantithymocyte globulin equine decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.antithymocyte globulin rabbitantithymocyte globulin rabbit decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.azathioprineazathioprine decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.basiliximabbasiliximab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.budesonidebudesonide decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.canakinumabcanakinumab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.cortisonecortisone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.deflazacortdeflazacort decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.dexamethasonedexamethasone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.elivaldogene autotemcelelivaldogene autotemcel, hepatitis A vaccine inactivated. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .etanerceptetanercept decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.everolimuseverolimus decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.fludrocortisonefludrocortisone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.glatiramerglatiramer decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.golimumabgolimumab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hydrocortisonehydrocortisone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.hydroxychloroquine sulfatehydroxychloroquine sulfate decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.infliximabinfliximab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.leflunomideleflunomide decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.methylprednisolonemethylprednisolone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.muromonab CD3muromonab CD3 decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.mycophenolatemycophenolate decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.ocrelizumabocrelizumab decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion.ofatumumab SCofatumumab SC decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible.prednisoloneprednisolone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.prednisoneprednisone decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.rilonaceptrilonacept decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.secukinumabsecukinumab decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease.siponimodsiponimod decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk.sirolimussirolimus decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.tacrolimustacrolimus decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.temsirolimustemsirolimus decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.teplizumabteplizumab decreases effects of hepatitis A vaccine inactivated by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment.tocilizumabtocilizumab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.triamcinolone acetonide injectable suspensiontriamcinolone acetonide injectable suspension decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines.Monitor Closely (21)certolizumab pegolcertolizumab pegol decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Use Caution/Monitor.cyclosporinecyclosporine decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). .dengue vaccinedengue vaccine, hepatitis A vaccine inactivated. unspecified interaction mechanism. Use Caution/Monitor. Data are not available to establish safety and immunogenicity of coadministration of dengue vaccine with recommended adolescent vaccines.ibrutinibibrutinib decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .ifosfamideifosfamide decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .lomustinelomustine decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .mechlorethaminemechlorethamine decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks